维普期刊资源整合服务平台（V6.5）

49篇 您的检索式：作者名="Leiter L"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Ongoing clinical trials of the pleiotropic effects of statins显示文摘	Davignon J Leiter L A		0，，01：	1
2	Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untrsnated region sequences 显示文摘	Rogers J T Leiter L M Mcphee J	1999	J Biol chem1999，294，：	1
3	Animal model of human disease, the non-obese diabetic (NOD) mouse显示文摘	Prochazka M Coleman D L	1987	Am J Path1987，128，2：	1
4	Therapeutic effects of dehydroepiandrosterone (DHEA) indiabeticmice 显示文摘	CPLEMAN D L LEITER E H SCHWEIZER R W	1982	Diabetes1982，31，：	1
5	1998 clinical practice guidelines for the management of diabetes in Canada 显示文摘	Meltzer S Leiter L Daneman D	1998	CMAJ1998，159，：	1
6	Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) uptitration of atorvastatin ( to 40 mg ) in hypercholesterolemic patients at moderately high risk for coronary heart disease 显示文摘	CONARD S E BAYS H E LEITER L A	2008	Am J Cardiol2008，102，11：	1
7	Use of insulin as- part, a fast-acting insulin analog, as the mealtime insulin in the management of patients with typel diabetes显示文摘	Raskin P Guthrie RA Leiter L	2000	Diabetes Care2000，23，：	1
8	A nonin-vasive intraoral electromyographic electrode for genioglos-sus muscle 显示文摘	DOBLE E A LEITER J C KNUTH S L	1985	J Appl Physiol1985，58，4：	1
9	Custom cerium oxide nanoparticles protect against a rice radical mediated autoimmune degenerative disease in the brain 显示文摘	Heckman K L DeCoteau W Estevez A Reed K J Costanzo W Sanford D Leiter J C Clauss J Knapp K Gomez C Mullen P Rathbun E Prime K Marini J Patchefsky J Patchefsky A S Hailstone R K Erli- chman J S	2013	ACS Nano2013，7，10：	1
10	Efficacy and safety of ezetimibe added on to atorvastatin (40 mg ) compared with uptitration of atorvastatin (to 80 mg ) in hypercholesterolemic patients at high risk of coronary heart disease显示文摘	LEITER L A BAYS H CONARD S	2008	Am J Cardiol2008，102，11：	1
11	Type 2 diabetes mellitus management in Canada: is it improving? 显示文摘	Leiter L A Berard L Bowering C K	2013	Can J Diabetes2013，37，2：	1
12	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines显示文摘	Cheng A Y Leiter L A	2006	Curr Opin Cardiol2006，21，4：	1
13	Ezetimibe add- ed to atorvastatin compared with doubling the atmwastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither 显示文摘	CONARD S BAYS H LEITER L A	2010	Diabetes Obes Metab2010，12，3：	1
14	The clinical burden of type 2 diabetes in patients with acute coronary syndromes:Prognosis and implications for short and long-term management显示文摘	KATZ P LEITER L A MELLBIN L	2014	Diabetes&Vascular Disease Research:Official Journal of the International Society of Diabetes and Vascular Disease2014，11，6：	1
15	Of the rennin-angiotensin-system and reactive oxygen species Type 2 diabetes and angiotensin Ⅱinhibition显示文摘	Leiter L A Lewanczuk R Z	2005	Am J Hypertens2005，18，1：	1
16	Postprandial glucose regulation: new data and implications显示文摘	Leiter L A Ceriello A Davidson J A	2003	Clin Ther2003，27，：	1
17	Use of insulin aspart,a fast-acting insulin analog,as the mealtime insulin in the management of patients with type 1 diabetes显示文摘	Raskin P Guthrie R A Leiter L	2000	Diabetes Care2000，23，5：	1
18	Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU):52 week results from a randomised,double-blind,phase 3 non-inferiority trial显示文摘	Cefalu W T Leiter L A Yoon K H	2013	Lancet2013，382，9896：	1
19	1998 Clinical practice guidelines for the management of diabetes in Canada 显示文摘	Meltzer S Leiter L Daneman D	1998	CMAJ1998，159，：	1
20	Use of insulin aspart: a fast-acting insulin analogue, as the mealtime insulin in the management of patients with type 1 diabetes显示文摘	Raskin P Guthne R A Leiter L	2000	Diabetes Care2000，23，5：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示